Antithrombin (AT) is a small glycoprotein that inactivates several enzymes of the coagulation system. It is a 464-amino-acid protein produced by the liver. It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin. Its activity is increased manyfold by the anticoagulant drug heparin, which enhances the binding of antithrombin to factor IIa (thrombin) and factor Xa.
Antithrombin is also termed antithrombin III (AT III). The designations antithrombin I through to antithrombin IV originate in early studies carried out in the 1950s by Seegers, Johnson and Fell.
Antithrombin I (AT I) refers to the binding of thrombin to fibrin, after thrombin has activated fibrinogen, at a non-catalytic binding site of thrombin. Antithrombin II (AT II) refers to a cofactor in plasma, which together with heparin interferes with the interaction of thrombin and fibrinogen. Antithrombin III (AT III) refers to a substance in plasma that inactivates thrombin. Antithrombin IV (AT IV) refers to an antithrombin that becomes activated during and shortly after blood coagulation. Only AT III and possibly AT I are medically significant. AT III is generally referred to solely as "antithrombin" and it is antithrombin III that is discussed in this article.
Antithrombin has a half-life in blood plasma of around 3 days.
The normal antithrombin concentration in human blood plasma is high at approximately 0.12 mg/ml, which is equivalent to a molar concentration of 2.3 μM.
Antithrombin has been isolated from the plasma of a large number of species additional to humans. As deduced from protein and cDNA sequencing, cow, sheep, rabbit and mouse antithrombins are all 433 amino acids in length, which is one amino acid longer than human antithrombin.
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.
Thrombin (, fibrinogenase, thrombase, thrombofort, topical, thrombin-C, tropostasin, activated blood-coagulation factor II, blood-coagulation factor IIa, factor IIa, E thrombin, beta-thrombin, gamma-thrombin) is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the clotting process. Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions.
Les serpines (de l'anglais serpin, mot-valise pour ine rotease hibitor) sont des protéines aux structures semblables, connues historiquement pour leur capacité à inhiber les protéases à sérine. Elles forment une superfamille de protéines présente à travers tous les règnes du vivant. Elles doivent leur nom au fait que les premières à avoir été identifiées inhibent les protéases à sérine de type chymotrypsine. Elles sont remarquables par leur mécanisme d'action, qui consiste à inhiber leur peptidase cible en subissant un changement conformationnel de grande amplitude qui fait disparaître le site actif.
La fibrine est une protéine filamenteuse issue du fibrinogène sous l'action de la thrombine lors de la coagulation sanguine. Elle appartient à la famille des protéines fibreuses. Il s'agit d'une des matières albuminoïdes du sang, qui en contient normalement 2 à 4 %. La fibrine, qui se rencontre aussi dans la lymphe et, en général, dans tous les exsudats séreux, se retire du sang par le battage. Elle se présente alors sous la forme de filaments blancs qui se voient dans le cas de plaies ulcéreuses.
Explore l'ingénierie des cellules immunitaires, y compris les stratégies de ciblage, la technologie des micronœuds et les progrès de la thérapie cellulaire CAR-T.
Explore l'ingénierie des cellules immunitaires pour la thérapie contre le cancer, en mettant l'accent sur le ciblage des inhibiteurs de contrôle par des méthodes d'administration novatrices.
Explore la découverte et l'importance de la bradykinine dans la vasomotricité artérielle et la vasodilatation.
, , ,
moleculARweb (https://molecularweb.epfl.ch) began as a website for education and outreach in chemistry and structural biology through augmented reality (AR) content that runs in the web browsers of regular devices like smartphones, tablets, and computers. ...
SWISS CHEMICAL SOC2022
In neurodegenerative diseases, a wide range of amyloid proteins or peptides such as amyloid-beta and alpha-synuclein fail to keep native functional conformations, followed by misfolding and self-assembling into a diverse array of aggregates. The aggregates ...
CAMBRIDGE UNIV PRESS2020
, , , ,
Life is a non-equilibrium phenomenon. Owing to their high free energy content, the macromolecules of life tend to spontaneously react with ambient oxygen and water and turn into more stable inorganic molecules. A similar thermodynamic picture applies to th ...